Prostate artery embolisation for benign prostatic hyperplasia
Vreugdenburg T, Wild C
Record ID 32017000328
English
Authors' recommendations:
There are four different types of embolisation agents (all CE-marked, none with FDA approval) that can be used in PAE, which vary in size and material. A total of three comparative studies with 306 patients are available for analysis of efficacy; the included RCTs make contradictory statements regarding improvements in IPSS and HRQoL after 12 months. The most commonly reported side effects associated with PAE in all studies were minor. Currently, five RCTs are ongoing comparing PAE to TURP, the end of which is scheduled for February 2021. A new evaluation is proposed in the year 2021, if results from RCTs are available by then.
Details
Project Status:
Completed
Year Published:
2017
URL for published report:
http://eprints.hta.lbg.ac.at/1118/1/DSD_105.pdf
URL for additional information:
http://eprints.hta.lbg.ac.at/1118/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Austria
MeSH Terms
- Arteries
- Embolization, Therapeutic
- Humans
- Male
- Prostate-Specific Antigen
- Prostatic Hyperplasia
Contact
Organisation Name:
Ludwig Boltzmann Institute for Health Technology Assessment
Contact Address:
Ludwig Boltzmann Institute for fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7/rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99
Contact Name:
tarquin.mittermayr@aihta.at
Contact Email:
office@aihta.at
Copyright:
Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.